Literature DB >> 31134495

Heterogeneity of Hepatic Cancer Stem Cells.

Caecilia H C Sukowati1,2.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality rate. It is a heterogeneous cancer with diverse inter- and intra-heterogeneity, also in terms of histology, prognosis, and molecular profiles. A rapidly growing evidence has demonstrated that some HCCs, if not all, were caused by the activation of the cancer stem cells (CSC), a small population within the cancer that is responsible for the initiation and maintenance of cancer growth. Until now, various populations of hepatic CSC with more than ten different phenotypical protein markers, such as CD133, CD90, EpCAM, CD24, and CD13, have been identified and validated in xenotransplantation models. They are associated with risk factors, prognosis, chemo-resistance, and metastasis. This chapter summarizes available data on different hepatic CSC markers for the development of potential future therapy.

Entities:  

Keywords:  CSC markers; CSC origin; Cancer heterogeneity; Cancer stem cells; Chemo-resistance; Hepatocellular carcinoma; Liver cancer; Prognosis; Stem cells; Targeted therapy; Tumor-initiating cells

Mesh:

Substances:

Year:  2019        PMID: 31134495     DOI: 10.1007/978-3-030-14366-4_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Expression of ALDH1A1 and CD133 is associated with the prognosis and effect of different chemotherapeutic regimens in gastric cancer.

Authors:  Wan-Ting Liu; Wen-Bo Liu; Min Gao; Yi-Yin Zhang; Kang-Sheng Gu
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

Review 2.  Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.

Authors:  Xiaomeng Dai; Yixuan Guo; Yan Hu; Xuanwen Bao; Xudong Zhu; Qihan Fu; Hangyu Zhang; Zhou Tong; Lulu Liu; Yi Zheng; Peng Zhao; Weijia Fang
Journal:  Theranostics       Date:  2021-01-19       Impact factor: 11.556

3.  The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations.

Authors:  An B Luong; Huy Q Do; Paola Tarchi; Deborah Bonazza; Cristina Bottin; Loraine Kay D Cabral; Long D C Tran; Thao P T Doan; Lory S Crocè; Hoa L T Pham; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

4.  Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.

Authors:  Alexander Bondoc; Kathryn Glaser; Kang Jin; Charissa Lake; Stefano Cairo; James Geller; Gregory Tiao; Bruce Aronow
Journal:  Commun Biol       Date:  2021-09-08

Review 5.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

Review 6.  Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.

Authors:  Loraine Kay D Cabral; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

7.  Human Hepatic Cancer Stem Cells (HCSCs) Markers Correlated With Immune Infiltrates Reveal Prognostic Significance of Hepatocellular Carcinoma.

Authors:  Xiaopu Sang; Fenfang Wu; Di Wu; Shan Lin; Jingyi Li; Nan Zhao; Xiaoni Chen; Anlong Xu
Journal:  Front Genet       Date:  2020-02-28       Impact factor: 4.599

Review 8.  Models for Understanding Resistance to Chemotherapy in Liver Cancer.

Authors:  Jose J G Marin; Elisa Herraez; Elisa Lozano; Rocio I R Macias; Oscar Briz
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

Review 9.  Two Faces of Autophagy in the Struggle against Cancer.

Authors:  Anna Chmurska; Karolina Matczak; Agnieszka Marczak
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.